In vitro activity and killing effect of the synthetic hybrid cecropin A-melittin peptide CA(1-7)M(2-9)NH(2) on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics.
The in vitro activity of CA(1-7)M(2-9)NH(2), a 15-residue synthetic hybrid peptide derived from the sequences of cecropin A and melittin, alone and in combination with amoxicillin-clavulanate, imipenem, clarithromycin, ciprofloxacin, rifampin, and vancomycin, was investigated against 40 nosocomial isolates of methicillin-resistant Staphylococcus aureus. Antimicrobial activity of CA(1-7)M(2-9)NH(2) was measured by minimal inhibitory concentration, MBC, and time-kill studies. All isolates were inhibited at concentrations of 1 to 16 microg/mL. Combination studies performed with S. aureusATCC 43300 demonstrated synergy only when CA(1-7)M(2-9)NH(2) was combined with amoxicillin-clavulanate and imipenem. Our findings show that CA(1-7)M(2-9)NH(2) is active against methicillin-resistant S. aureusand that its activity is enhanced when it is combined with several antimicrobial agents.
Giacometti
Andrea
A
Institute of Infectious Diseases and Public Health, University of Ancona, Ancona, Italy. anonacmi@interfree.it
Cirioni
Oscar
O
Kamysz
Wojciech
W
D'Amato
Giuseppina
G
Silvestri
Carmela
C
Simona Del Prete
Maria
M
Lukasiak
Jerzy
J
Scalise
Giorgio
G
D019980:Amoxicillin-Potassium Clavulanate Combination / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy; D004347:Drug Interactions; D005260:Female; D006801:Humans; D015378:Imipenem / Q000494:pharmacology*; D008297:Male; D008555:Melitten / Q000494:pharmacology*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D012680:Sensitivity and Specificity; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification
D008555:Melitten; D015378:Imipenem; D019980:Amoxicillin-Potassium Clavulanate Combination